{"answer":{"query":"calquence","resolved_as":"name","packages":2,"applications":["NDA216387"],"identity":{"application_numbers":["NDA216387"],"marketing_categories":["NDA"],"labelers":[{"text":"ASTRAZENECA PHARMACEUTICALS LP","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2022-08-04","latest":"2022-08-04","packages_with_a_start_date":1}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":2,"negotiated_price_ends":null,"rows":[{"ndc":"00310051260","name":{"text":"CALQUENCE 100MG 60CT","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00310351260","name":{"text":"CALQUENCE TAB 100MG BT 1X60 EA US","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":8600,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA216387","date":"2036-07-01","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"11059829","productNo":"001"},"latest_patent_expiry":"2036-07-01","latest_exclusivity_expiry":"2029-02-19","dated_barriers":10,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":8,"exclusivities_listed":2,"fact_id":"7295b047fcdc1d4f8429ce17"}],"label_history":{"events_total":3,"non_cmc_events":3,"counts_by_class":{"EFFICACY":2,"LABELING":1},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA216387","submission_no":6,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-02-19","documents":[{"type":"Letter","date":"2026-02-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/210259Orig1s012, 216387Orig1s006ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-02-24","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216387s006lbl.pdf","untrusted":true}}],"fact_id":"f296cda98b6620c26380a7e8"},{"application":"NDA216387","submission_no":5,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-01-16","documents":[{"type":"Label","date":"2025-01-17","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216387s005lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-01-17","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/210259Orig1s011;216387Orig1s005ltr.pdf","untrusted":true}}],"fact_id":"ef518fb1b8fbe16678612266"},{"application":"NDA216387","submission_no":4,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-06-05","documents":[{"type":"Label","date":"2024-06-06","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216387s004lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-07-02","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/216387Orig1s004ltr.pdf","untrusted":true}}],"fact_id":"987aa02823db93a70fef4603"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA216387","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"CALQUENCE","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"EQ 100MG BASE","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":1,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"ACALABRUTINIB","untrusted":true},"recruiting_interventional_count":37,"not_yet_recruiting_count":4,"by_phase":{"PHASE2":19,"PHASE1/PHASE2":6,"PHASE3":7,"PHASE4":1,"PHASE1":2,"NA":1,"PHASE2/PHASE3":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT07582159","title":{"text":"Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"City of Hope Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-12-19","link":{"text":"https://clinicaltrials.gov/study/NCT07582159","untrusted":true}},{"nct_id":"NCT06054776","title":{"text":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"City of Hope Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2024-12-02","link":{"text":"https://clinicaltrials.gov/study/NCT06054776","untrusted":true}},{"nct_id":"NCT04404088","title":{"text":"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"M.D. Anderson Cancer Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2020-07-16","link":{"text":"https://clinicaltrials.gov/study/NCT04404088","untrusted":true}},{"nct_id":"NCT05952024","title":{"text":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"AstraZeneca","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2024-07-16","link":{"text":"https://clinicaltrials.gov/study/NCT05952024","untrusted":true}},{"nct_id":"NCT06520098","title":{"text":"A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"VA Office of Research and Development","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2025-10-01","link":{"text":"https://clinicaltrials.gov/study/NCT06520098","untrusted":true}}],"fact_id":"351fa16e5964cfcf54f60d3a"}]},"spending":{"reported_under":{"generic":{"text":"Acalabrutinib Maleate","untrusted":true},"brand":{"text":"Calquence","untrusted":true}},"latest_year":2024,"series":[{"year":2022,"gross_spending_usd":164376683.03,"claims":11685,"beneficiaries":5519,"average_spending_per_claim_usd":14067.324179,"fact_id":"555f270ac2eeb3ac719955a0"},{"year":2023,"gross_spending_usd":1286819830.1,"claims":89978,"beneficiaries":12390,"average_spending_per_claim_usd":14301.494033,"fact_id":"d67bb2aead7239c3181e7351"},{"year":2024,"gross_spending_usd":1701974920.8,"claims":122356,"beneficiaries":15056,"average_spending_per_claim_usd":13910.024198,"fact_id":"94ffe04c2685b4fbe3b5592c"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"acalabrutinib","untrusted":true},"designation_count":6,"approved_count":5,"recent":[{"designated":"2015-10-22","use":{"text":"Treatment of Waldenstrom macroglobulinemia.","untrusted":true},"status":"Designated","sponsor":{"text":"Acerta Pharma, LLC (a member of the AstraZeneca Group)","untrusted":true},"approved":false},{"designated":"2015-09-21","use":{"text":"Treatment of mantle cell lymphoma.","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Acerta Pharma, LLC (a member of the AstraZeneca Group)","untrusted":true},"approved":true},{"designated":"2015-09-21","use":{"text":"Treatment of mantle cell lymphoma.","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Acerta Pharma, LLC (a member of the AstraZeneca Group)","untrusted":true},"approved":true},{"designated":"2015-09-21","use":{"text":"Treatment of mantle cell lymphoma.","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Acerta Pharma, LLC (a member of the AstraZeneca Group)","untrusted":true},"approved":true},{"designated":"2015-05-13","use":{"text":"Treatment of chronic lymphocytic leukemia (CLL).","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Acerta Pharma, LLC (a member of the AstraZeneca Group)","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"7258b7af5ca212cd319c02c0"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":3,"all_states_medicaid_reimbursed_usd":3726817.32,"all_states_medicaid_paid_prescriptions":264,"top_states":[{"state":"KY","medicaid_paid_prescriptions":96,"medicaid_reimbursed_usd":1393440.48,"total_reimbursed_usd":1393440.48,"packages":1,"covers":"all_record_types","fact_id":"4d83bd72cd7bf3004963bae4"},{"state":"MN","medicaid_paid_prescriptions":93,"medicaid_reimbursed_usd":1195935.57,"total_reimbursed_usd":1195935.57,"packages":1,"covers":"fee_for_service_only","fact_id":"ced370022806492897aa92d4"},{"state":"LA","medicaid_paid_prescriptions":75,"medicaid_reimbursed_usd":1137441.27,"total_reimbursed_usd":1137441.27,"packages":1,"covers":"all_record_types","fact_id":"ff234ec4e657b9d61654f102"}],"unlabelled_state_code_xx":null,"built_from_facts":3,"facts_fee_for_service_only":1,"older_year_facts_not_used":24,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"5799fb8161b800cc729fd60c","field":"ndc.listing","entity":"ndc:00310351260"},{"fact_id":"7295b047fcdc1d4f8429ce17","field":"drug.generic_entry_earliest","entity":"application:NDA216387"},{"fact_id":"eaf904816d6f29cad1e56c5a","field":"drug.patent","entity":"application:NDA216387"},{"fact_id":"c90639e5d167430f650f025a","field":"drug.exclusivity","entity":"application:NDA216387"},{"fact_id":"f296cda98b6620c26380a7e8","field":"drug.label_event","entity":"application:NDA216387"},{"fact_id":"ef518fb1b8fbe16678612266","field":"drug.label_event","entity":"application:NDA216387"},{"fact_id":"987aa02823db93a70fef4603","field":"drug.label_event","entity":"application:NDA216387"},{"fact_id":"2613cfb76c12011eb7e1b243","field":"drug.marketing_status","entity":"application:NDA216387"},{"fact_id":"351fa16e5964cfcf54f60d3a","field":"drug.trial_access","entity":"drug:acalabrutinib"},{"fact_id":"555f270ac2eeb3ac719955a0","field":"drug.partd_spending","entity":"drug:acalabrutinib-maleate|calquence"},{"fact_id":"d67bb2aead7239c3181e7351","field":"drug.partd_spending","entity":"drug:acalabrutinib-maleate|calquence"},{"fact_id":"94ffe04c2685b4fbe3b5592c","field":"drug.partd_spending","entity":"drug:acalabrutinib-maleate|calquence"},{"fact_id":"7258b7af5ca212cd319c02c0","field":"drug.orphan_designation","entity":"drug:acalabrutinib"},{"fact_id":"4d83bd72cd7bf3004963bae4","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310351260:KY"},{"fact_id":"ced370022806492897aa92d4","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310351260:MN"},{"fact_id":"ff234ec4e657b9d61654f102","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00310351260:LA"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"AMBIGUOUS","field":"spending","reason":"2 brand and generic name pairs match; the series shown is the one with the newest year and the largest spending"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}